Zydus Cadila has signed a collaborative research agreement with the Council of Scientific and Industrial Research (CSIR) - Institute of Microbial Technology (IMTECH), Government of India. The research partnership will primarily aim to identify new drug candidates for treatment of drug-resistant infections.
The agreement between CSIR-IMTECH and the company will see scientists from both organizations working closely together on microbiology & genomics to identify new lead candidate as novel anti-tuberculosis compounds. For this project, scientists at IMTECH will utilize their expertise and scientific knowledge in microbiology, while Zydus Cadila will provide its expertise in medicinal chemistry & pharmaceutical drug development with an aim to develop new drug combinations against drug-resistant pathogens which causes severe diseases in India and across the world.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1935.25 |
| Dr. Reddys Labs. | 1245.50 |
| Cipla | 1438.75 |
| Zydus Lifesciences | 1150.50 |
| Lupin | 2496.05 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: